AIML.CN C$0.035 CNQ 21 Jan 2026: microcap AI health pick needs catalysts
The AIML.CN stock trades at C$0.035 on the CNQ exchange in Canada as of 21 Jan 2026. This microcap digital-health firm uses AI and ML for wearable and monitoring tools but posts negative earnings and thin market liquidity. Volume today is 843,196.00 shares, well above the 50-day average of 383,847.00, signaling short-term interest. We examine valuation, technicals, and Meyka AI model forecasts for AIML.CN stock to show where risk and opportunity sit for AI-focused portfolios.
AIML.CN stock price snapshot and intraday flow
AIML.CN stock is quoted at C$0.035 with a day range of C$0.035–C$0.035 and previous close C$0.035. Volume hit 843,196.00, a relative volume of 2.20, which suggests above-normal trading interest. The 50-day average price sits at C$0.0384 and the 200-day average is C$0.05798, both above today’s price, reflecting a downtrend over months.
One clear fact: the stock is microcap with a market cap of C$5,889,240.00, so price swings often reflect low liquidity rather than broad market moves. That amplifies volatility for AI investors focused on small AI/ML names.
AIML.CN stock fundamentals and valuation
AI/ML Innovations Inc. reports EPS of -0.03 and a PE of -1.17, indicating current unprofitability. Price to sales is 35.00 and price to book is 4.58, both high relative to typical healthcare-tech peers. Cash per share is 0.00532 and book value per share is 0.00747, leaving scant balance-sheet cushions.
Operating metrics show a current ratio of 2.09, low operating cash flow per share of -0.02635, and net income per share of -0.03104. These figures signal ongoing cash burn and negative margins, important for investors allocating to AI stocks within healthcare.
AIML.CN stock technicals and market action
Technical indicators are mixed for AIML.CN stock. RSI is 40.70, ADX 14.53 (no trend), and Bollinger Bands show a tight band at C$0.03–C$0.04. The 3-month price change is down 36.36% and one-year change is down 76.67%, reflecting a sustained decline.
On-chain volume signals show OBV at -3,369,524.00, which matches the long-term selling pressure. Traders focused on AI momentum should treat this as a high-risk swing trade, not a liquid core holding.
Meyka AI grade, model forecast and outlook for AIML.CN stock
Meyka AI rates AIML.CN with a score out of 100. Meyka AI rates AIML.CN with a score of 57.98 (Grade C+) and suggests HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a 12-month price near C$0.01710 versus the current C$0.035, implying an estimated downside of -51.14%. Forecasts are model-based projections and not guarantees. Investors should weigh the model output against the company’s product milestones and cash runway.
Catalysts, risks and AIML.CN stock sector context
Catalysts for AIML.CN stock would include FDA or regulatory progress, commercial partnerships, or clear clinical validation of wearable systems. The healthcare sector shows mixed returns; Canadian healthcare peers report an average 1-year performance of 11.68%, making AIML.CN an outlier on the downside.
Key risks include limited liquidity, negative margins, and stretched valuation metrics like price-to-sales of 35.00. Sector headwinds and slow adoption of proprietary AI wearables could further pressure the stock.
Price targets, scenario planning and trading strategy for AIML.CN stock
There is no published analyst consensus price target for AIML.CN stock. For planning we offer scenario targets: a conservative bear target C$0.01, base case C$0.035, and speculative bull C$0.12. Use tight position sizing given the microcap nature.
For AI-focused portfolios, treat AIML.CN as a high-beta, high-risk exposure. Consider stop-losses near C$0.02 and reassess after any news on clinical data or commercial deals.
Final Thoughts
AIML.CN stock at C$0.035 is a microcap AI-in-health name with active volume but weak fundamentals. The company posts EPS -0.03, negative operating cash flow, and a market cap of C$5,889,240.00, which limits institutional interest. Meyka AI assigns a grade of C+ (57.98) and the model projects C$0.01710 in 12 months, an implied downside of -51.14% from today’s price. That projection highlights the near-term risk for investors seeking AI exposure in healthcare.
Investors allocating to AI stocks should view AIML.CN as speculative. Potential upside hinges on product validation or strategic partnerships. Monitor volume spikes, regulatory news, and cash runway closely. For timely alerts and model updates visit our AIML.CN stock page on Meyka AI and follow global AI coverage from Reuters and The Wall Street Journal for sector context source source and our internal AIML.CN stock page for live updates Meyka AI AIML.CN page. Forecasts are model-based projections and not guarantees.
FAQs
What is the current price and volume for AIML.CN stock
AIML.CN stock trades at C$0.035 on CNQ with today’s volume 843,196.00, above the 50-day average 383,847.00. High relative volume reflects short-term trader interest in this microcap name.
What is Meyka AI’s forecast for AIML.CN stock
Meyka AI’s forecast model projects C$0.01710 in 12 months for AIML.CN stock. Compared to the current C$0.035, that implies an estimated downside near -51.14%. Forecasts are model-based and not guarantees.
How does AIML.CN stock rank on fundamentals and risk
AIML.CN stock shows negative EPS -0.03, price-to-sales 35.00, and weak cash flow per share -0.02635. Those metrics indicate high financial risk for investors seeking stable AI/ML exposure.
What catalysts could move AIML.CN stock
Key catalysts include clinical validation, regulatory steps, or commercial partnerships for its wearable AI platform. Any clear revenue growth or partnership announcements would likely drive price action given the microcap liquidity.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
